scholarly journals Risk Factors for Sensorineural Hearing Loss Among High-Risk Infants in Golestan Province, Iran in 2010 - 2011

2015 ◽  
Vol 17 (12) ◽  
Author(s):  
Ehsan Alaee ◽  
Mohsen Sirati ◽  
Mohammad Hossein Taziki ◽  
Mahnaz Fouladinejad
1986 ◽  
Vol 89 (2) ◽  
pp. 135-141
Author(s):  
NORIKO NISHIZAWA ◽  
TOSHIKI MANABE ◽  
SHINJI NISHIZAWA

2021 ◽  
Vol 11 ◽  
Author(s):  
Miranda L. Camet ◽  
Anne Spence ◽  
Susan S. Hayashi ◽  
Ningying Wu ◽  
Jennifer Henry ◽  
...  

BackgroundSensorineural hearing loss is a well-known side effect of cisplatin (CDDP). There is limited research on the effect of dosing, infusion times, and schedules of cisplatin administration and their impact on hearing loss.MethodsA retrospective review of 993 pediatric patients’ medical and audiological charts from August 1990 to March 2015 was conducted using stringent inclusion criteria to characterize patients with hearing loss. 248 of these patients received CDDP. Of these, 216 patients had sufficient CDDP infusion data to assess for sensorineural hearing loss attributable to CDDP and its associated risk factors. Chart reviews were performed to extract clinical data including CDDP dosing information. Demographic and clinical characteristics were summarized by descriptive statistics, and univariate and multivariate logistic regressions were performed to examine the relationship between hearing loss and specific parameters of cisplatin administration (amount infused per dose, prescribed infusion time, total number of doses, number of doses per cycle, number of cycles, cumulative cisplatin exposure). Stepwise variable selection procedure was performed in the multivariate model building to extract the best subset of risk factors for the prediction of hearing loss and worsening ototoxicity grade using an established ototoxicity grading scale from the International Society of Pediatric Oncology (SIOP).ResultsA total of 153 patients with complete medical and audiologic data were evaluable for analysis. Hearing loss was identified in 72.6% of the patients. Multivariate analysis revealed that age [OR=0.90 (0.84-0.97), p-value=0.0086], radiation to any part of the body, [OR=3.20 (1.29-7.93), p-value=0.012], amount infused per dose (mg/m2) [OR=1.018 (1.002-1.033), p-value=0.029], and cumulative cisplatin exposure (mg/m 2) [OR=1.004 (1-1.008), p-value=0.027] were associated with hearing loss. Similar associations were also found between these risk factors and worsening SIOP grade.ConclusionIn one of the largest studies examining the influence of CDDP dosing and schedules on hearing loss, we found the amount of CDDP infused per dose is a significant risk factor. Considerations in designing regimens that reduce the amount of CDDP infused per dose may reduce the risk of hearing loss. Randomized prospective trials are needed.


2012 ◽  
Vol 63 (5) ◽  
pp. 382-390 ◽  
Author(s):  
Faustino Núñez-Batalla ◽  
Germán Trinidad-Ramos ◽  
José Miguel Sequí-Canet ◽  
Valentín Alzina De Aguilar ◽  
Carmen Jáudenes-Casaubón

2007 ◽  
Vol 28 (7) ◽  
pp. 878-883 ◽  
Author(s):  
Gabriella Cadoni ◽  
Simona Scipione ◽  
Stefania Agostino ◽  
Giovanni Addolorato ◽  
Francesca Cianfrone ◽  
...  

2012 ◽  
Vol 17 (6) ◽  
pp. 400-408 ◽  
Author(s):  
F. Ballesteros ◽  
D. Tassies ◽  
J.C. Reverter ◽  
I. Alobid ◽  
M. Bernal-Sprekelsen

Sign in / Sign up

Export Citation Format

Share Document